Plexus Ventures Assists Sanofi Consumer Health to Divest a Product Portfolio in Australia and South-East Asia to Phoenix Labs

May 5, 2023

Philadelphia, Pennsylvania – Phoenix Labs (“Phoenix”) has acquired a portfolio of well-established consumer health products from Sanofi Consumer Health (“Sanofi”).  The portfolio includes Proctosedyl™, the leading pharmacy-only haemorrhoid treatment in Australia and a number of Essential Remedies found in many Australian homes. Additionally, the divestment package includes the Proctosedyl™ business in China, Malaysia, New Zealand, Singapore, Taiwan, Thailand and Ireland, and Anthisan® in New Zealand

Plexus Ventures, a leading healthcare business development advisory firm established in 1990, assisted the Sanofi Consumer Health team with the divestment process leading to the closing of the transaction. “We are pleased to complete this divestment for Sanofi. We helped to generate intense competition for these assets demonstrating, once again, our capabilities in mature product divestments. This transaction allows Phoenix to reinforce its presence and commercial capabilities in Australia, New Zealand and South-East Asia,” commented Gabriele Tundo, Plexus Ventures’ Partner.

About Plexus Ventures

Plexus Ventures has earned the title Business Builders in Healthcare over nearly three decades as a leading corporate and business development consultancy for healthcare industry companies. Plexus assists clients of all sizes and capabilities to achieve their strategic business development objectives. Plexus industry professionals are conveniently located in the United States, Europe and Asia-Pacific markets, enabling Plexus to benefit its clients with both local knowledge and global reach.

Trending

News

Celon Pharma enters agreement with Zydus Lifesciences Ltd.

Philadelphia, Pennsylvania – Plexus Ventures is pleased to announce the successful conclusion of a licensing agreement of behalf of our client, Celon Pharma. Mr. Michael O’Sullivan, Plexus Ventures’ Managing Partner, stated: “This transaction is an ideal match which...